Cidara Therapeutics Inc (CDTX)
13.43
+0.40
(+3.07%)
USD |
NASDAQ |
Nov 05, 16:00
13.43
0.00 (0.00%)
After-Hours: 20:00
Cidara Therapeutics Revenue (Quarterly): 0.302M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.302M |
| March 31, 2024 | 8.463M |
| December 31, 2023 | 17.58M |
| September 30, 2023 | 12.72M |
| June 30, 2023 | 5.09M |
| March 31, 2023 | 26.11M |
| December 31, 2022 | 10.38M |
| September 30, 2022 | 40.74M |
| June 30, 2022 | 6.216M |
| March 31, 2022 | 7.109M |
| Date | Value |
|---|---|
| December 31, 2021 | 7.225M |
| September 30, 2021 | 7.076M |
| June 30, 2021 | 32.86M |
| March 31, 2021 | 2.408M |
| December 31, 2020 | 3.729M |
| September 30, 2020 | 2.416M |
| June 30, 2020 | 3.392M |
| March 31, 2020 | 2.53M |
| December 31, 2019 | 1.815M |
| September 30, 2019 | 19.10M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.302M
Minimum
Jun 2024
40.74M
Maximum
Sep 2022
10.43M
Average
7.076M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 745.74M |
| Arbutus Biopharma Corp | 1.726M |
| GlycoMimetics Inc | -- |
| FibroGen Inc | 50.64M |
| Cue Biopharma Inc | 2.658M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -91.21M |
| Total Expenses (Quarterly) | 11.40M |
| EPS Diluted (Quarterly) | -19.99 |
| Enterprise Value | -72.66M |
| Profit Margin (Quarterly) | -30.20K% |
| Earnings Yield | -188.2% |
| Normalized Earnings Yield | -54.58 |